Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2327949 in chronic kidney disease due to type 2 diabetes or hypertension
NL-OMON49199Phase 2Withdrawn
- Sponsor
- Bayer
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing BAY 2327949 with Placebo (2 arms). Primary endpoint: Decrease in urine albumin-to-creatinine ratio versus baseline. Planned start Sep 2020; status: withdrawn.
02
Drugs
enuvaptan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON49199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49199.